IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, today announced the MultiCyt™ QBeads™ PlexScreen family of reagents. It is the first commercially available product to enable multiplexed analysis of secreted proteins at the pace and price needed for screening and the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools.
“The addition of MultiCyt QBeads PlexScreen to our reagent portfolio is a key part of our strategy to offer an integrated screening solution, especially for key therapeutic areas like immunology, toxicology and oncology,” commented Terry Dunlay, CEO at IntelliCyt. “QBeads use immunochemistry to capture specific secreted proteins on distinct bead types. Our innovative no wash protocol and low volume requirements enables multiplexed analysis of secreted proteins such as cytokines, adhesion molecules, enzymes and receptors at the speed and price demanded by screeners.”
About IntelliCyt Corporation
IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research.